FIB-4 Score is a simple formula to predict liver fibrosis based on the standard biochemical / hematological values i.e. AST, ALT, Platelet count and age. The Score lower than 1.45 has a Negative Predictive Value (NPV) of 95% for significant fibrosis i.e. F3-F4 while, a Score of greater than 3.25 has a PPV of 80% for advance fibrosis i.e. F3-F4. So an improvement of FIB-4 Score is a possible indicator of change in liver fibrosis. The objective is to observe the disparity in paired FIB-04 Score in hepatitis C patients treated with pegylated interferon and ribavirin at the beginning of the treatment and at the end of treatment evaluation (ETR). An observational study was carried out in patients with mono-infected, compensated CHC patients ,treated with Pegylated Interferon & Ribavirin for 24weeks to 48 weeks (according to genotype)in a tertiary care hospital (i.e. Baqai Medical University Hospital Nazimabad) from Jan 2010 to March 2015 in a paired manner i.e. before (at beginning) and at the End of treatment evaluation (ETR). Responses were analyzed by using ‘Wilcoxon signed rank test. SPSS 23.00 version was used to analyze data. Fifty eight patients diagnosed with hepatitis C took part in the study out of which 24 were males (41.4%) with mean age 38.8 (22y-60y) and 34 were females (58.6%) with mean age 43.6 (31y-60y). Out of 58 participants, 8 patients were type 1 genotype, 48 patients were type 3 genotype and 1 was type 4. Genotype of 1 participant was not recorded. According to result evaluated, there is a statically significant decrease in FIB04 score from beginning of treatment (M=2.52, SD=1.35) to ETR (M=1.74, SD=1.37) justifying that there is a definite positive change in FIB-04 score (i.e. improvement in fibrosis). Distinct positive change in FIB-4 Score was observed in Chronic Hepatitis C patients treated with pegylated interferon/ribavirin at the end of treatment